Although no in vitro potentiation by erlotinib of PARP-induced cytotoxic effect was observed, this combination was very effective in the suppression of ERK1/2 activation (Figure 4B) and, more interestingly, in vivo co-treatment was synergic in slowing-down tumour growth. The gene discussed is MAPK3; the disease is neoplasm.